Review



polyclonal antibody against her-2/neu (1:1,600)  (Agilent technologies)


Bioz Verified Symbol Agilent technologies is a verified supplier
Bioz Manufacturer Symbol Agilent technologies manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Agilent technologies polyclonal antibody against her-2/neu (1:1,600)
    Polyclonal Antibody Against Her 2/Neu (1:1,600), supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+antibodies+against+her-2/pmc03445894-77-22-29?v=Agilent+technologies
    Average 90 stars, based on 1 article reviews
    polyclonal antibody against her-2/neu (1:1,600) - by Bioz Stars, 2026-08
    90/100 stars

    Images



    Similar Products

    polyclonal antibody against her-2/neu (1:1,600)  (Agilent technologies)
    90
    Agilent technologies polyclonal antibody against her-2/neu (1:1,600)
    Polyclonal Antibody Against Her 2/Neu (1:1,600), supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+antibodies+against+her-2/pmc03445894-77-22-29?v=Agilent+technologies
    Average 90 stars, based on 1 article reviews
    polyclonal antibody against her-2/neu (1:1,600) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    polyclonal antibodies against her-2  (Agilent technologies)
    90
    Agilent technologies polyclonal antibodies against her-2
    Polyclonal Antibodies Against Her 2, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+antibodies+against+her-2/pm30025999-48-21-27?v=Agilent+technologies
    Average 90 stars, based on 1 article reviews
    polyclonal antibodies against her-2 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    polyclonal rabbit antibodies against her-2  (Agilent technologies)
    90
    Agilent technologies polyclonal rabbit antibodies against her-2
    Polyclonal Rabbit Antibodies Against Her 2, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+antibodies+against+her-2/pmc04466969-55-28-33?v=Agilent+technologies
    Average 90 stars, based on 1 article reviews
    polyclonal rabbit antibodies against her-2 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    polyclonal serum against human her 2  (R&D Systems)
    94
    R&D Systems polyclonal serum against human her 2
    Polyclonal Serum Against Human Her 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+antibodies+against+her-2/pm21645926-51-21-26?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    polyclonal serum against human her 2 - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    polyclonal antibodies against p-her-2 (tyr877)  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc polyclonal antibodies against p-her-2 (tyr877)
    Polyclonal Antibodies Against P Her 2 (Tyr877), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+antibodies+against+her-2/pm21453385-38-4-14?v=Cell+Signaling+Technology+Inc
    Average 90 stars, based on 1 article reviews
    polyclonal antibodies against p-her-2 (tyr877) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    polyclonal antibody against her‐2/neu  (Agilent technologies)
    90
    Agilent technologies polyclonal antibody against her‐2/neu
    The prognostic significance of high protein interacting with C α kinase 1 (PICK1) protein expression in the entire patient population. The graphs show the effect of PICK1 expression within cancer cells (a) on patient overall survival (log‐rank test) and stratified analysis by lymph nodes status (b), <t>Her‐2/neu</t> status (c), hormone receptor (HR) status (d), and molecular subclassification (e–h). High PICK1 expression in cancer cells (a) associated with decreased overall survival (OS) (P < 0.0001, respectively). When patients’ OS were stratified by lymph node status, Her‐2/neu status, hormone receptor status, and molecular subclassification status, PICK1 expression was associated with reduced OS in the Her‐2/neu‐positive and ‐negative (c, P = 0.019 and P = 0.003, respectively), HR‐positive and ‐negative (d, P = 0.007 and P < 0.0001, respectively), and lymph node ‐positive subgroups (b, P < 0.0001). Molecular subclassification: HR−/HER‐2+ and HR−/HER‐2− (g–f, P = 0.0.041 and P = 0.002, respectively).
    Polyclonal Antibody Against Her‐2/Neu, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+antibodies+against+her-2/pmc11159445-145-42-38?v=Agilent+technologies
    Average 90 stars, based on 1 article reviews
    polyclonal antibody against her‐2/neu - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    polyclonal antibodies against her 2  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc polyclonal antibodies against her 2
    The prognostic significance of high protein interacting with C α kinase 1 (PICK1) protein expression in the entire patient population. The graphs show the effect of PICK1 expression within cancer cells (a) on patient overall survival (log‐rank test) and stratified analysis by lymph nodes status (b), <t>Her‐2/neu</t> status (c), hormone receptor (HR) status (d), and molecular subclassification (e–h). High PICK1 expression in cancer cells (a) associated with decreased overall survival (OS) (P < 0.0001, respectively). When patients’ OS were stratified by lymph node status, Her‐2/neu status, hormone receptor status, and molecular subclassification status, PICK1 expression was associated with reduced OS in the Her‐2/neu‐positive and ‐negative (c, P = 0.019 and P = 0.003, respectively), HR‐positive and ‐negative (d, P = 0.007 and P < 0.0001, respectively), and lymph node ‐positive subgroups (b, P < 0.0001). Molecular subclassification: HR−/HER‐2+ and HR−/HER‐2− (g–f, P = 0.0.041 and P = 0.002, respectively).
    Polyclonal Antibodies Against Her 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+antibodies+against+her-2/10__1074_slash_jbc__m701803200-49-0-10?v=Cell+Signaling+Technology+Inc
    Average 97 stars, based on 1 article reviews
    polyclonal antibodies against her 2 - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    polyclonal antibodies against tyrosine-phosphorylated her-2  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc polyclonal antibodies against tyrosine-phosphorylated her-2
    The prognostic significance of high protein interacting with C α kinase 1 (PICK1) protein expression in the entire patient population. The graphs show the effect of PICK1 expression within cancer cells (a) on patient overall survival (log‐rank test) and stratified analysis by lymph nodes status (b), <t>Her‐2/neu</t> status (c), hormone receptor (HR) status (d), and molecular subclassification (e–h). High PICK1 expression in cancer cells (a) associated with decreased overall survival (OS) (P < 0.0001, respectively). When patients’ OS were stratified by lymph node status, Her‐2/neu status, hormone receptor status, and molecular subclassification status, PICK1 expression was associated with reduced OS in the Her‐2/neu‐positive and ‐negative (c, P = 0.019 and P = 0.003, respectively), HR‐positive and ‐negative (d, P = 0.007 and P < 0.0001, respectively), and lymph node ‐positive subgroups (b, P < 0.0001). Molecular subclassification: HR−/HER‐2+ and HR−/HER‐2− (g–f, P = 0.0.041 and P = 0.002, respectively).
    Polyclonal Antibodies Against Tyrosine Phosphorylated Her 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+antibodies+against+her-2/10__1074_slash_jbc__m701803200-49-5-10?v=Cell+Signaling+Technology+Inc
    Average 90 stars, based on 1 article reviews
    polyclonal antibodies against tyrosine-phosphorylated her-2 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The prognostic significance of high protein interacting with C α kinase 1 (PICK1) protein expression in the entire patient population. The graphs show the effect of PICK1 expression within cancer cells (a) on patient overall survival (log‐rank test) and stratified analysis by lymph nodes status (b), Her‐2/neu status (c), hormone receptor (HR) status (d), and molecular subclassification (e–h). High PICK1 expression in cancer cells (a) associated with decreased overall survival (OS) (P < 0.0001, respectively). When patients’ OS were stratified by lymph node status, Her‐2/neu status, hormone receptor status, and molecular subclassification status, PICK1 expression was associated with reduced OS in the Her‐2/neu‐positive and ‐negative (c, P = 0.019 and P = 0.003, respectively), HR‐positive and ‐negative (d, P = 0.007 and P < 0.0001, respectively), and lymph node ‐positive subgroups (b, P < 0.0001). Molecular subclassification: HR−/HER‐2+ and HR−/HER‐2− (g–f, P = 0.0.041 and P = 0.002, respectively).

    Journal: Cancer Science

    Article Title: Protein interacting with C α kinase 1 (PICK1) is involved in promoting tumor growth and correlates with poor prognosis of human breast cancer

    doi: 10.1111/j.1349-7006.2010.01566.x

    Figure Lengend Snippet: The prognostic significance of high protein interacting with C α kinase 1 (PICK1) protein expression in the entire patient population. The graphs show the effect of PICK1 expression within cancer cells (a) on patient overall survival (log‐rank test) and stratified analysis by lymph nodes status (b), Her‐2/neu status (c), hormone receptor (HR) status (d), and molecular subclassification (e–h). High PICK1 expression in cancer cells (a) associated with decreased overall survival (OS) (P < 0.0001, respectively). When patients’ OS were stratified by lymph node status, Her‐2/neu status, hormone receptor status, and molecular subclassification status, PICK1 expression was associated with reduced OS in the Her‐2/neu‐positive and ‐negative (c, P = 0.019 and P = 0.003, respectively), HR‐positive and ‐negative (d, P = 0.007 and P < 0.0001, respectively), and lymph node ‐positive subgroups (b, P < 0.0001). Molecular subclassification: HR−/HER‐2+ and HR−/HER‐2− (g–f, P = 0.0.041 and P = 0.002, respectively).

    Article Snippet: The antibodies and the dilution factors were as follows: polyclonal antibody against PICK1 (1:75) from ProteinTech Group (Chicago, IL, USA); Dako Clone ID5 antibody against ER (1:450) (Carpinteria, CA, USA); Dako Clone IA6 antibody against PR (1:200); and Dako polyclonal antibody against Her‐2/neu (1:1000).

    Techniques: Expressing